Desensitization protocols and their outcome

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 4, 2011, Pages 922-936

  Marfo, Kwaku ^a   Lu, Amy ^a   Ling, Min ^a   Akalin, Enver ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIBODY; ANTIGEN; BASILIXIMAB; BORTEZOMIB; COMPLEMENT COMPONENT C4D; DACLIZUMAB; ECULIZUMAB; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ALLOGRAFT; ANAPHYLAXIS; ANTIBODY SPECIFICITY; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; BACKACHE; BIOPSY; BLOOD PRESSURE; CHILL; CHRONIC GRAFT REJECTION; DEEP VEIN THROMBOSIS; DESENSITIZATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FLUORESCENCE; FOLLOW UP; GLOMERULOPATHY; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH ECONOMICS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOADSORPTION; INFECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MYALGIA; MYCOSIS; NAUSEA; OUTCOME ASSESSMENT; PLASMAPHERESIS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PREVENTIVE HEALTH SERVICE; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; SIDE EFFECT; SPLENECTOMY; STROKE; SYSTEMATIC REVIEW; THERAPY EFFECT;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOPSY; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; KIDNEY TRANSPLANTATION; RISK ASSESSMENT; WAITING LISTS;

EID: 79955560884     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08140910     Document Type: Article

References (107)

1. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K: Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 270: 1339-1343, 1993
2. Russell JD, Beecroft ML, Ludwin D, Churchill DN: The quality of life in renal transplantation-A prospective study. Transplantation 54: 656-660, 1992
3. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Ag-odoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725-1730, 1999
4. Akalin E: Posttransplant immunosuppression in highly sensitized patients. Contrib Nephrol 162: 27-34, 2009
5. Hakim RM, Milford E, Himmelfarb J, Wingard R, Lazarus JM, Watt RM: Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 16: 423-431, 1990
6. Pescovitz MD: Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 6: 859-866, 2006
7. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD: Proteasome inhibition causes apopto-sis of normal human plasma cells preventing alloantibody production. Am J Transplant 9: 201-209, 2009
8. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M: Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 89: 903-904, 2010
9. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Wurzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W: Prophylactic eculizumab after renal transplantation in atypica hemolytic-uremic syndrome. N Engl J Med 362: 1746-1748, 2010
10. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747-755, 2001
11. Watanabe J, Scornik JC: IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idio-typic activity. Am J Transplant 5: 2786-2790, 2005
12. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, Berkower I, Sto-jilkovic SS, Metcalfe DD: F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins. Nat Med 9: 431-438, 2003
13. Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 484-486, 2001
14. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E: Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 83: 99-100, 2007
15. Locke JE, Zachary AA, Haas M, Melancon JK, Warren DS, Simpkins CE, Segev DL, Montgomery RA: The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 7: 842-846, 2007
16. Montgomery RA, Zachary AA: Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant 8: 535-542, 2004
17. Schweitzer EJ, Wilson JS, Fernandez-Vina M, Fox M, Gutierrez M, Wiland A, Hunter J, Farney A, Philosophe B, Colonna J, Jarrell BE, Bartlett ST: A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 70: 1531-1536, 2000
18. Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Ny-berg SL, Larson TS, Griffin MD, Textor SC, Velosa JA, Schwab TR, Fix LA, Stegall MD: Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 3: 1017-1023, 2003
19. Magee CC, Felgueiras J, Tinckam K, Malek S, Mah H, Tullius S: Renal transplantation in patients with positive lymphocyto-toxicity crossmatches: One center's experience. Transplantation 86: 96-103, 2008
20. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, Kaplan B, Benedetti E, Oberholzer J: Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 87: 268-273, 2009
21. Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C, Jacobs S, Drachenberg C, Bartlett S, Cooper M: Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 9: 536-542, 2009
22. Tyan DB, Li VA, Czer L, Trento A, Jordan SC: Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 57: 553-562, 1994
23. Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, Schwieger J, Steiner RW, Davis C, Tyan DB: Post-transplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66: 800-805, 1998
24. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puli-yanda D, Kamil E, Tyan D: Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76: 631-636, 2003
25. Vo AA, Toyoda M, Peng A, Bunnapradist S, Lukovsky M, Jordan SC: Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 6: 2384-2390, 2006
26. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reins-moen NL, Villicana R, Jordan SC: Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sen-sitized patients awaiting kidney transplantation. Transplantation 89: 1095-1102, 2010
27. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: 242-251, 2008
28. Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, Reinsmoen N, Jordan SC: Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 8: 144-149, 2008
29. Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, Hacen C, Duboust A, Bariety J: Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2: 758-760, 2002
30. Lefaucheur C, Nochy D, Hill GS, Suberbielle-Boissel C, An-toine C, Charron D, Glotz D: Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 7: 832-841, 2007
31. Akalin E, Bromberg JS: Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 66: 359-363, 2005
32. Mai ML, Ahsan N, Wadei HM, Genco PV, Geiger XJ, Will-ingham DL, Taner CB, Hewitt WR, Grewal HP, Nguyen JH, Hughes CB, Gonwa TA: Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 87: 227-232, 2009
33. Bächler K, Amico P, Honger G, Bielmann D, Hopfer H, Mi-hatsch MJ, Steiger J, Schaub S: Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies. Am J Transplant 10: 1254-1262, 2010
34. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S: A comparison of plasmapheresis versus high-dose IVIG desensi-tization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6: 346-351, 2006
35. Akalin E, Ames S, Sehgal V, Fotino M, Daly L, Murphy B, Bromberg JS: Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell cross-match-positive patients. Transplantation 76: 1444-1447, 2003
36. Akalin E, Ames S, Sehgal V, Murphy B, Bromberg JS, Fotino M, Friedlander R: Intravenous immunoglobulin and thymo-globulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 79: 742, 2005
37. Akalin E, Dinavahi R, Friedlander R, Ames S, de Boccardo G, Sehgal V, Schroppel B, Bhaskaran M, Lerner S, Fotino M, Murphy B, Bromberg JS: Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 3: 1160-1167, 2008
38. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J: Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 15: 3256-3262, 2004
39. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, Roggero AL, Fineberg NS, Taber T, Kraus MA, Pescovitz MD: Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77: 542-548, 2004
40. Higgins RM, Bevan DJ, Carey BS, Lea CK, Fallon M, Buhler R, Vaughan RW, O'Donnell PJ, Snowden SA, Bewick M, Hendry BM: Prevention of hyperacute rejection by remova of antibodies to HLA immediately before renal transplantation. Lancet 348: 1208-1211, 1996
41. Haas M, Bohmig GA, Leko-Mohr Z, Exner M, Regele H, Der-fler K, Horl WH, Druml W: Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 17: 1503-1508, 2002
42. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K, Druml W, Bohmig GA: Peritransplant immunoadsorption: A strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 79: 696-701, 2005
43. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, An-toine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boisse C: Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 21: 1398-1406, 2010
44. Haas M, Montgomery RA, Segev DL, Rahman MH, Racusen LC, Bagnasco SM, Simpkins CE, Warren DS, Lepley D, Zach-ary AA, Kraus ES: Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 7: 576-585, 2007
45. Kraus ES, Parekh RS, Oberai P, Lepley D, Segev DL, Bagnasco S, Collins V, Leffell M, Lucas D, Rabb H, Racusen LC, Singer AL, Stewart ZA, Warren DS, Zachary AA, Haas M, Montgomery RA: Subclinical rejection in stable positive crossmatch kidney transplant patients: Incidence and correlations. Am J Transplant 9: 1826-1834, 2009
46. Loupy A, Suberbielle-Boissel C, Hill GS, Lefaucheur C, Angli-cheau D, Zuber J, Martinez F, Thervet E, Mejean A, Charron D, van Huyen JP, Bruneval P, Legendre C, Nochy D: Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 9: 2561-2570, 2009
47. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Rand-hawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ: Banff'05 Meeting Report: Differentia diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 7: 518-526, 2007
48. Gloor JM, Sethi S, Stegall MD, Park WD, Moore SB, DeGoey S, Griffin MD, Larson TS, Cosio FG: Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 7: 2124-2132, 2007
49. Issa N, Cosio FG, Gloor JM, Sethi S, Dean PG, Moore SB, DeGoey S, Stegall MD: Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 86: 681-685, 2008
50. Akalin E, Dinavahi R, Dikman S, de Boccardo G, Friedlander R, Schroppel B, Sehgal V, Bromberg JS, Heeger P, Murphy B: Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2: 1261-1267, 2007
51. Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, DeGoey SR, Lager DJ, Grande JP, Stegall MD: Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6: 1841-1847, 2006
52. Gloor JM, Winters JL, Cornell LD, Fix LA, DeGoey SR, Knauer RM, Cosio FG, Gandhi MJ, Kremers W, Stegall MD: Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 10: 582-589, 2010
53. Rafiq MA, de Boccardo G, Schroppel B, Bromberg JS, Sehgal V, Dinavahi R, Murphy B, Akalin E: Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant 23: 951-957, 2009
54. Akalin E, Watschinger B: Antibody-mediated rejection. Semin Nephrol 27: 393-407, 2007
55. Kieran N, Wang X, Perkins J, Davis C, Kendrick E, Bakthavat-salam R, Dunbar N, Warner P, Nelson K, Smith KD, Nicosia RF, Alpers CE, Leca N, Kowalewska J: Combination of peritu-bular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 20: 2260-2268, 2009
56. Mizutani K, Terasaki P, Hamdani E, Esquenazi V, Rosen A, Miller J, Ozawa M: The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 7: 1027-1031, 2007
57. Burns JM, Cornell LD, Perry DK, Pollinger HS, Gloor JM, Kre-mers WK, Gandhi MJ, Dean PG, Stegall MD: Alloantibody levels and acute humoral rejection early after positive cross-match kidney transplantation. Am J Transplant 8: 2684-2694, 2008
58. Reinsmoen NL, Lai CH, Vo A, Cao K, Ong G, Naim M, Wang Q, Jordan SC: Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 86: 820-825, 2008
59. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, An-drade J, Antoine C, Gautreau C, Charron D, Glotz D: Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 8: 324-331, 2008
60. Higgins R, Hathaway M, Lowe D, Lam F, Kashi H, Tan LC, Imray C, Fletcher S, Zehnder D, Chen K, Krishnan N, Hamer R, Briggs D: Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: Resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 84: 876-884, 2007
61. Riethmuller S, Ferrari-Lacraz S, Muller MK, Raptis DA, Ha-daya K, Rusi B, Laube G, Schneiter G, Fehr T, Villard J: Donor-specific antibody levels and three generations of cross-matches to predict antibody-mediated rejection in kidney transplantation. Transplantation 90: 160-167, 2010
62. Patel AM, Pancoska C, Mulgaonkar S, Weng FL: Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 7: 2371-2377, 2007
63. Locke JM, Simpkins CE, Leffell MS, Zachary AA, Collins V, Warren DS, Segev DL, Singer AL, Haas M, Montgomery RA: Induction immunosuppression in crossmatch positive renal transplant recipients: Results of a randomized controlled clinical trial [Abstract] Am J Transplant 9[suppl 2]: 241, 2009
64. Wahrmann M, Exner M, Schillinger M, Haidbauer B, Regele H, Kormoczi GF, Horl WH, Bohmig GA: Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Am J Transplant 6: 1033-1041, 2006
65. Bartel G, Wahrmann M, Exner M, Regele H, Huttary N, Schillinger M, Kormoczi GF, Horl WH, Bohmig GA: In vitro detection of C4d-fixing HLA alloantibodies: Associations with capillary C4d deposition in kidney allografts. Am J Transplant 8: 41-49, 2008
66. Hönger G, Wahrmann M, Amico P, Hopfer H, Bohmig GA, Schaub S: C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 89: 1471-1475, 2010
67. Toyoda M, Pao A, Vo A, Lukovsky M, Radha R, Sado T, Ge S, Reinsmoen N, Chai NN, Baden L, Petrosyan A, Skinner E, Mirocha J, Jordan SC: Intracellular IFNgamma production in CD3 negative cells exposed to allo-antigens is an indicator of prior sensitization. Transpl Immunol 22: 121-127, 2009
68. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP: The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 7: 402-407, 2007
69. Perry DK, Pollinger HS, Burns JM, Rea D, Ramos E, Platt JL, Gloor JM, Stegall MD: Two novel assays of alloantibody-se-creting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 8: 133-143, 2008
70. Akalin E, Pascual M: Sensitization after kidney transplantation. Clin J Am Soc Nephrol 1: 433-440, 2006
71. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S: Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 87: 1681-1688, 2009
72. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, Tsai A, Lei HY: All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74: 1192-1194, 2002
73. Terasaki PI, Ozawa M, Castro R: Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 7: 408-415, 2007
74. Lee PC, Zhu L, Terasaki PI, Everly MJ: HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88: 568-574, 2009
75. Gloor JM, DeGoey S, Ploeger N, Gebel H, Bray R, Moore SB, Dean PG, Stegall MD: Persistence of low levels of alloanti-body after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 78: 221-227, 2004
76. Zachary AA, Montgomery RA, Leffell MS: Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immuno-globulin. Hum Immunol 66: 364-370, 2005
77. Zachary AA, Montgomery RA, Ratner LE, Samaniego-Picota M, Haas M, Kopchaliiska D, Leffell MS: Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 76: 1519-1525, 2003
78. Bartel G, Regele H, Wahrmann M, Huttary N, Exner M, Horl WH, Bohmig GA: Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 8: 2652-2660, 2008
79. Feucht HE, Mihatsch MJ: Diagnostic value of C4d in renal biopsies. Curr Opin Nephrol Hypertens 14: 592-598, 2005
80. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hun-sickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection cri-teria-An addition to the Banff 97 classification of renal allo-graft rejection. Am J Transplant 3: 708-714, 2003
81. Racusen LC, Halloran PF, Solez K: Banff 2003 meeting report: New diagnostic insights and standards. Am J Transplant 4: 1562-1566, 2004
82. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M: Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 8: 753-760, 2008
83. Magil AB, Tinckam KJ: Focal peritubular capillary C4d deposition in acute rejection. Nephrol Dial Transplant 21: 1382-1388, 2006
84. Fidler ME, Gloor JM, Lager DJ, Larson TS, Griffin MD, Textor SC, Schwab TR, Prieto M, Nyberg SL, Ishitani MB, Grande JP, Kay PA, Stegall MD: Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 4: 101-107, 2004
85. Haas M, Rahman MH, Racusen LC, Kraus ES, Bagnasco SM, Segev DL, Simpkins CE, Warren DS, King KE, Zachary AA, Montgomery RA: C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: Correlation with his-tologic findings. Am J Transplant 6: 1829-1840, 2006
86. Kato M, Morozumi K, Takeuchi O, Oikawa T, Koyama K, Usami T, Shimano Y, Ito A, Horike K, Otsuka Y, Toda S, Takeda A, Uchida K, Haba T, Kimura G: Complement fragment C4d deposition in peritubular capillaries in acute humoral rejection after ABO blood group-incompatible human kidney transplantation. Transplantation 75: 663-665, 2003
87. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF: Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 9: 2312-2323, 2009
88. Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, Lavayssiere L, Cointault O, Ribes D, Cardeau I, Nogier MB, Durand D, Abbal M, Blancher A, Ros-taing L: Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10: 89-98, 2010
89. Jordan S, Cunningham-Rundles C, McEwan R: Utility of intravenous immune globulin in kidney transplantation: Efficacy, safety, and cost implications. Am J Transplant 3: 653-664, 2003
90. Vo AA, Cam V, Toyoda M, Puliyanda DP, Lukovsky M, Bun-napradist S, Peng A, Yang K, Jordan SC: Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: A single-center experience. Clin J Am Soc Nephrol 1: 844-852, 2006
91. Kahwaji J, Barker E, Pepkowitz S, Klapper E, Villicana R, Peng A, Chang R, Jordan SC, Vo AA: Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 4: 1993-1997, 2009
92. Sekul EA, Cupler EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 121: 259-262, 1994
93. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES: Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 86: 1754-1761, 2008
94. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Candon S, Martinez F, Snanoudj R, Rabant M, Pallet N, Nochy D, An-glicheau D, Leruez M, Loupy A, Thervet E, Hermine O, Leg-endre C: Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 10: 681-686, 2010
95. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khem-chandani SI, Dave SD: Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 87: 1555-1561, 2009
96. Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogil-ishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES: Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 89: 277-284, 2010
97. Raghavaiah SR, Diwan TS, Burns JM, Gloor JM, Gandhi MJ, Winters JL, Groettum CM, Dean PG, Stegall MD: Depletion of alloantibody-secreting plasma cells by proteasome inhibition improves desensitization [Abstract]. Am J Transplant 10[suppI4]: 44, 2010
98. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, Stewart ZA, Warren DS, Zachary AA, Montgomery RA: The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 9: 231-235, 2009
99. Gloor J, Stegall MD: Sensitized renal transplant recipients: Current protocols and future directions. Nat Rev Nephrol 6: 297-306, 2010
100. Cornell LD, Gloor M, Nasr SH, Fidler ME, Sethi S, Diwan T, Burns M, Cosio FG, Stegall MD: Chronic humoral rejection despite C5 Inhibition after positive-crossmatch kidney transplantation [abstract]. Am J Transplant 10[suppl4]: 125, 2010
101. Tillou X, Poirier N, Le Bas-Bernardet S, Hervouet J, Minault D, Renaudin K, Vistoli F, Karam G, Daha M, Soulillou JP, Blancho G: Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 78: 152-159, 2010
102. Vincenti F, Cohen SD, Appel G: Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases. Clin J Am Soc Nephrol 5: 142-151, 2010
103. Rapaport FT: The case for a living emotionally related international kidney donor exchange registry. Transplant Proc 18: 5-9, 1986
104. Ross LF, Rubin DT, Siegler M, Josephson MA, Thistlethwaite JR, Woodle ES: Ethics of a paired-kidney-exchange program. N Engl J Med 336: 1752-1755, 1997
105. Montgomery RA, Gentry SE, Marks WH, Warren DS, Hiller J, Houp J, Zachary AA, Melancon JK, Maley WR, Rabb H, Simpkins C, Segev DL: Domino paired kidney donation: A strategy to make best use of live non-directed donation. Lancet 368: 419-421, 2006
106. Rees MA, Kopke JE, Pelletier RP, Segev DL, Rutter ME, Fabrega AJ, Rogers J, Pankewycz OG, Hiller J, Roth AE, Sandholm T, Unver MU, Montgomery RA: A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med 360: 1096-1101, 2009
107. Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA: Kidney paired donation and optimizing the use of live donor organs. JAMA 293: 1883-1890, 2005